StockNews.com assumed coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research report report published on Sunday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Performance
Shares of TTNP opened at $3.81 on Friday. Titan Pharmaceuticals has a 52 week low of $3.57 and a 52 week high of $14.80. The business has a 50-day simple moving average of $4.81 and a two-hundred day simple moving average of $5.70.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last released its earnings results on Thursday, August 15th. The specialty pharmaceutical company reported ($2.29) earnings per share (EPS) for the quarter.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Recommended Stories
- Five stocks we like better than Titan Pharmaceuticals
- Retail Stocks Investing, Explained
- Warren Buffett, Cathie Wood Own Nu Holdings, Should You?
- What Are Some of the Best Large-Cap Stocks to Buy?
- MercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?
- What is Forex and How Does it Work?
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
